checkAd

     161  0 Kommentare Kinarus Therapeutics Holding AG ('Kinarus') receives deadline extension from SER for publication of its 2022 annual financial report

    Kinarus Therapeutics Holding AG / Key word(s): Annual Results
    Kinarus Therapeutics Holding AG ('Kinarus') receives deadline extension from SER for publication of its 2022 annual financial report

    28-Apr-2023 / 07:00 CET/CEST
    Release of an ad hoc announcement pursuant to Art. 53 LR
    The issuer is solely responsible for the content of this announcement.


    Ad hoc announcement pursuant to Art. 53 LR

    Basel, Switzerland, 28 April 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases announced that on 27 April 2023 SIX Exchange Regulation ("SER") approved a deadline extension until the end of May 2023 for the publication of the Kinarus 2022 annual financial report. In addition, in line with the decision of SER, Kinarus will publish certain unaudited key financial figures for the financial year 2022 by 5 May 2023.

    In accordance with the regulations of SIX Swiss Exchange, Kinarus applied to SER for an extension of the deadline for publication of its 2022 annual financial report. Kinarus is currently finalizing the financial statements on a consolidated basis, including its subsidiaries, as required for the annual financial reporting requirements. Such finalization had to be deferred due to various outstanding information and the verification of such information. Also, Kinarus only recently became a listed company after completion of the reverse takeover in June 2022 and various processes relating to financial reporting of Kinarus had to be established within a very short period of time. Ernst & Young, Kinarus’ auditors will conclude its audit of the financial statements as soon as possible upon receiving the required input from Kinarus.

    “The Kinarus management and board of directors are working intensively to finalize the 2022 annual financial report and are confident that the audited financial statements will be published in the course of May 2023" said Alexander Bausch, CEO of Kinarus.

    As required by SER, Kinarus hereby reprints para. I of SER’s decision (translation from German original):

    I. The exemption from obligations for the maintaining of the listing and, therefore, the extension of the deadline to publish the 2022 annual report and to file such report with SIX Exchange Regulation AG by Wednesday, 31 May 2023 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):

    Seite 1 von 2



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    Kinarus Therapeutics Holding AG ('Kinarus') receives deadline extension from SER for publication of its 2022 annual financial report Kinarus Therapeutics Holding AG / Key word(s): Annual Results Kinarus Therapeutics Holding AG ('Kinarus') receives deadline extension from SER for publication of its 2022 annual financial report 28-Apr-2023 / 07:00 CET/CEST Release of an ad hoc …

    Schreibe Deinen Kommentar

    Disclaimer